18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a single centre, single arm feasibility study of 18FCH PET-MR imaging for staging patients with high risk prostate cancer.

Study Hypothesis:

FCH-PET/MR will enable more accurate staging of patients with high risk prostate cancer as compared to conventional imaging.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborators: Prostate Cancer Canada; Prostate Cancer Canada Network

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Histologic diagnosis of carcinoma of prostate

• High risk disease: defined as Gleason ≥8, or T3 disease, or PSA >20ng/mL

• No prior therapy for prostate cancer (surgery, radiation therapy, hormone therapy, chemotherapy).

• Ability to provide written informed consent to participate in the study

Exclusion Criteria:

• Prior surgery or radiation therapy for prostate cancer

• Prior or ongoing hormone or other systemic therapy for prostate cancer

• Inability to lie supine for 90 minutes

• Any contraindication to MR as per Joint Department of Medical Imaging policies.

• Impaired kidney function with glomerular filtration rate < 30ml/min

• Previous anaphylactic reaction to gadolinium or other contraindications to MR.